MRgLITT for TLE: A PROBE Trial

Launched by BEIJING TIANTAN HOSPITAL · Dec 3, 2024

Keywords

ClinConnect Summary

The MRgLITT for TLE: A PROBE Trial is studying a new treatment approach called magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) for people with temporal lobe epilepsy (TLE), a type of epilepsy that does not respond well to medication. This trial aims to understand how effective this therapy is in improving the health and daily lives of those with drug-resistant epilepsy. The trial is currently looking for participants of all ages who have been diagnosed with TLE and have not found relief from their seizures through medications.

To be eligible, participants need to have epilepsy that is resistant to drugs, meaning their current medications aren't controlling their seizures. However, individuals with certain serious health issues or those who have had previous brain surgeries won't be able to participate due to higher risks associated with the treatment. For those who join the trial, they can expect to undergo the MRgLITT procedure and will be closely monitored to see how it affects their seizures and overall well-being. This trial is a valuable opportunity for those looking for new options to manage their epilepsy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Drug-resistant epilepsy.
• • Temporal lobe epilepsy.
• • Participants approved.
• Exclusion Criteria:
• • Individuals with significant medical comorbidities or conditions that pose an excessive risk for surgery, such as severe cardiovascular disease, respiratory disorders, or uncontrolled systemic infections.
• • Brain surgery history.